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Abstract 
Polypharmacy increases the risk of drug-drug interactions (DDI’s). Combining epidemiological studies 
with pharmacokinetic modeling, we detected and evaluated high-dimensional DDI’s among thirty 
frequent drugs. Multi-drug combinations that increased risk of myopathy were identified in the FDA 
Adverse Event Reporting System (FAERS) and electronic medical record (EMR) databases by a mixture 
drug-count response model. CYP450 inhibition was estimated among the 30 drugs in the presence of 1 
to 4 inhibitors using in vitro in vivo extrapolation. Twenty-eight 3-way and 43 4-way DDI’s had significant 
myopathy risk in both databases and predicted increases in the area under the concentration time curve 
ratio (AUCR) >2-fold.  The HD-DDI of omeprazole, fluconazole and clonidine was associated with a 6.41-
fold (FAERS) and 18.46-fold (EMR) increase risk of myopathy (LFDR<0.005); the AUCR of omeprazole in 
this combination was 9.35.The combination of health record informatics and pharmacokinetic modeling 
is a powerful translational approach to detect high-dimensional DDI’s. 
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Introduction 
Drug-drug interactions (DDIs) are a common cause of adverse drug events (ADE) (1-3). In the United 
States alone, each year an estimated 195,000 hospitalizations and 74,000 emergency room visits are the 
result of DDIs. National Health and Nutrition Examination Survey data published in 2010 (4) showed that 
the number of patients using two or more prescription drugs increased from 25.4% to 31.2% in ten years. 
In particular, more than 64% of elderly individuals took three or more prescription drugs, and 37% took 
five or more prescription drugs (4). In the FDA Adverse Event Reporting System (FAERS) data, 35% of 
reports include three or more prescription drugs, and 20% reports have five or more prescription drugs. 
In order to evaluate clinical effects and molecular mechanisms of DDIs, clinical pharmacokinetic 
(PK) studies, pharmaco-epidemiologic studies, and in vitro PK experiments have been routinely utilized. 
One salient example is that of breast cancer hormonal therapy, tamoxifen. The formation of its active 
metabolite, endoxifen, was inhibited by concomitant selective serotonin reuptake inhibitor paroxetine 
in a clinical pharmacokinetics study (5). In vitro metabolism studies revealed that this is due to 
paroxetine’s strong inhibition of the tamoxifen bio-transformation to endoxifen via the CYP2D6 pathway 
(6). In a follow-up pharmacogenetic study, breast cancer patients with CYP2D6 loss function variants 
have a higher risk of disease relapse and a lower incidence of hot flush (7). The clinical consequence of 
treating breast cancer and depression using tamoxifen and SSRIs was reviewed (8), and a call made for 
further investigation. Another example is the sedation agent midazolam. Co-administration of 
midazolam and ergosterol synthesis inhibitor ketoconazole has been identified to reduced subjects’ 
cognitive function (9). In clinical PK and in vitro experiments, midazolam metabolism was inhibited by 
ketoconazole through the CYP3A pathway (10, 11), leading to increased midazolam exposure (12). 
These examples clearly demonstrate that the translational significance of drug interaction 
studies relies on both clinical and molecular pharmacology evidence. As described by Hennessy and 
Flockhart (13), an integrated informatics, epidemiology, and pharmacology approach has the potential 
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to accelerate the translational drug interaction studies. Pioneered by Tatonetti et al. (14), FAERS and 
electronic medical records were utilized to generate and validate drug-ADE and drug-drug-ADE 
associations. In a follow-up study, Lorberbaum et al. demonstrated that patients co-administrated 
ceftriaxone and lansoprazole were 1.4 times as likely to have a prolong QT prolongation than the 
administrated single drug in both EMR and FAERS data. Further validation showed that 
ceftriaxone/lansoprazole drug interaction was due to hERG channel blocker in a patch-clamp 
experiment system (15). Duke et al. proposed a text mining strategy for DDI molecular pharmacology 
evidence discovery from the public literature (16), which discovered 13,197 potential DDIs. In the 
follow-up in vitro study, Han et al. validated the loratadine‐simvastatin myotoxicity interaction, and its 
increased myopathy risk in both EMR and FAERS databases (17). Similarly, Schelleman et al. examined 
the increased risk of hypoglycaemia with co-administration of fibrates and statins in sulfonylurea users 
in a pharmaco-epidemiology study (18). This DDI was further evaluated in an in vitro in vivo 
extrapolation (IVIVE) pharmacokinetic model. 
High dimensional drug interactions (HDDIs), i.e. DDIs with three or more drugs, have not yet 
been broadly investigated. There are a few examples of clinical PK studies, in vitro PK experiments, and 
IVIVE PK models that evaluate interactions among 3 or more drugs. Co-administration of gemfibrozil and 
itraconazole were shown to increase repaglinide plasma exposure to a greater extent than either one 
alone (19). Zhang et al. found an additive PK model, including mechanism-based and competitive 
components, best described the in vitro inhibition of midazolam metabolism by erythromycin, diltiazem 
and their metabolites (20). Through IVIVE, this model was confirmed in vivo in mice (21). On the other 
hand, to our knowledge, there are no studies of three way drug interactions using pharmaco-
epidemiology studies. Proportional reporting ratio (PRR) (22), the reporting odds ratio (ROR) (23), the 
information component (IC) (24), and the empirical Bayes geometric mean (EBGM) (25) have been 
proposed for detection of drug-ADE signals. However, these methods are focused on ADE detection for 
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single drugs, not drug combination. To overcome this limitation, we have recently developed a new 
method, a mixture drug-count response model (MDCM). This model focuses on detecting high 
dimensional drug interactions, and characterizes the drug-count response relationship between the 
number of co-administered drugs and an ADE. We have successfully demonstrated its statistical and 
computational performance in a recent publication (26). 
In this paper, we will use this newly developed MDCM to detect HDDIs that lead to increased 
risk of myopathy in two independent databases: Indiana Network of Patient Care - CDM (INPC-CDM) 
electronic medical record and FAERS. Using in vitro cytochrome P450 (CYP) inhibition data and 
mechanistic static in vitro in vivo DDI predictions, we evaluate the potential pharmacological 
mechanisms of these HDDIs. 
 
Results 
Drug Selections 
As our MDCM is computationally expensive, we limited this analysis to top 30 drugs. After normalizing 
drug names by their DrugBank IDs, 1,238 and 1,716 FDA approved drugs were identified in the INPC-
CDM and FAERS datasets. Of these, after selecting drugs 268 and 172 drugs in INPC-CDM and FAERS, 
respectively, had a relative frequency ≥0.5%, with 119 drugs overlapping both databases. Among these 
119 drugs, 95 have reported myopathy risk according to SIDER (http://sideeffects.embl.de/). We curated 
the in vitro pharmacokinetic data for these 119 drugs to determine their potential to interact via CYP450 
inhibition. Nine drugs had reported fraction metabolism (fm) by human CYP450 enzymes. These drugs 
were evaluated as substrates for the prediction of area under the concentration-time curve ratio in the 
presence to absence of inhibitor (AUCR). Published competitive inhibition (ki) values for at least one 
CYP450 enzyme were available for 64 of the drugs. The top 23 drugs with inhibition ranked by 
𝑓𝑢×𝐶𝑚𝑎𝑥
𝑘𝑖
 
were selected as inhibitors (Figure 1). 
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INPC-CDM and FAERS Show Strikingly Different Drug-Count Myopathy Response Mixture Models 
Under the MDCM, each drug combination has a probability of being assigned to either a drug-count 
myopathy response model or a constant myopathy risk model. The drug-count response model and 
constant model share the same myopathy risk when subjects take only one drug. The drug-count 
myopathy response model captures the overall trend of the nonlinear relationship between the number 
of co-administered drugs and myopathy risk. It also characterizes a constant myopathy risk and the 
maximum myopathy risk as the number of co-administered drugs increases. Strikingly, the drug-count 
response model demonstrated very different trends between drug combinations and myopathy risk in 
INPC-CDM and FAERS databases. INPC-CDM had constant myopathy risk of 0.42, and maximum risk of 
0.74; while FAERS data shows constant risk of 0.07 and a maximum risk of 1.0 (Figure 2). In the INPC-
CDM, the maximum myopathy risk occurs when the four drugs are co-administered. However, in the 
FAERS, the myopathy risk continues to increase beyond 5-drug combinations. 
Overlapping Drug Combinations in INPC-CDM and FAERS 
The drug-count-response mixture model generates a local false discovery rate (LFDR) statistic that 
allows us to differentiate drug combinations that are more likely to follow the drug-response myopathy 
risk model than the constant risk model. Figure 3 shows the percentage of overlapping drug 
combinations that are shared between two databases, with a LFDR of 0.05. We see strong and 
consistent evidence of increased myopathy risk with an overlap of 37-40% of 2-way to 5-way drug 
combinations shown to increase myopathy risk in both databases.  
The Overall Trend of High Dimensional Drug Interactions in Pharmacokinetics Predicted by IVIVE 
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One common mechanism of drug-drug interaction occurs through inhibition of drug metabolism.  In 
order to assess whether the potential DDIs identified by pharmaco-epidemiology evidence are due to 
pharmacokinetic drug interactions, we used IVIVE to evaluate the change in drug exposure between a 
drug administered alone and co-administered with 2-, 3-, or more drugs. In the IVIVE prediction, CYP 
substrates and CYP inhibitors are differentially defined. Among our 30 selected drugs, nine are CYP 
substrates with curated fm, fe, and fu data from the literature. We also obtained the ki, fu, and Cmax for 23 
drugs identified as CYP inhibitors. These data were combined through IVIVE to predict the area under 
the concentration time curve ratio (AUCR) for 156 two-way, 1302 three-way, 6971 four-way, and 26901 
five-way drug interaction combinations (Figure 4). When we look at all the AUCR data under different 
dimensions of drug interactions, their medians, 75th percentiles, and the maximum AUCRs all reach a 
maximum plateau with the co-administration of 3 drugs. 
 
Sensitivity Analyses of Significant Three-way Drug Interactions  
Among the 9 substrates and 23 inhibitors, 28 three-way drug interactions have a predicted AUCR >2 and 
a LFDR from the MDCM model < 0.05. We hypothesized that among these drugs, the risk of myopathy 
would increase as the number of co-occurring drugs increased. Therefore, for each 3-drug combination 
we evaluated myopathy risk between individuals taking 1 drug vs any 2-drug combination, and between 
2-drug and 3-drug combinations. One drug-triplet showed a strong increasing trend in myopathy risk: 
omeprazole, clonidine, and fluconazole (Figure 5) after adjusting for the number of additional co-
medications, age, and gender. In the FAERS data set, taking any two of these three drugs together 
increased the risk of myopathy by 1.88-fold compared to taking any of the drugs alone (p = 0.012). 
Taking the 3-drug combination of omeprazole, clonidine and fluconazole increased the risk of myopathy 
by 5.01-fold compared to the 2-drug combinations (p = 0.000012). In the INPC-CDM, taking any two of 
these drugs concurrently increased the risk of myopathy by 1.75-fold (p=7.8E-13) and taking all three 
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together increased the risk by 4.18-fold (p=0.0069) compared to taking one drug and two drugs, 
respectively. Similar comparisons of 2- and 3-drug combinations to 1- and 2 drug combinations for the 
other 27 drug triplets examined did not reveal significantly increased myopathy risk in both data sets for 
other drug combinations (Table S1). 
The AUCRs of omeprazole due to the inhibition by clonidine and fluconazole alone or together were 
estimated from literature data using mechanistic static interaction models (27). Omeprazole is a racemic 
mixture of R- and S-omeprazole. While both enantiomers are metabolized by CYP2C19 and CYP3A 
(Figure 6), the fm’s for each pathway are slightly different (Table S2). Fluconazole is a well-known 
CYP2C19 and CYP3A inhibitor with a median ki value of 5.075 µM and 13.25 µM, respectively (28-30). 
The ki of clonidine for CYP3A is 0.15 µM (31). Incorporating these values into the IVIVE model (Equation 
4), predicts AUCRs of R- and S-omeprazole of 1.45 and 1.35, respectively, after the clonidine inhibition, 
and 5.06 and 5.17 after fluconazole inhibition. Following co-administration of the 3 drugs, the AUCRs of 
R- and S-omeprazole are predicted to be 9.35 and 8.51, respectively. Alternatively, the fm of omeprazole 
can also be estimated from pharmacogenetics PK study. Venkatakrishnan et al. calculated the fm of 
omeprazole from AUCR of CYP2C19 extensive metabolizer and poor metabolizer (32, 33) (fm = 0.87 for 
CYP2C19). Using this fm, the AUCR estimated from IVIVE is predicted to be 1.14 after the clonidine 
inhibition; 5.99 after fluconazole inhibition; and 7.69 after inhibition by both drugs. 
Discussion 
Using the MDCM, we mined the high dimensional drug interactions among 30 common drugs in two 
independent health record databases. We identified a number of high-dimensional drug interactions 
that have increased risk of myopathy in both databases. This model further reveals interesting 
differences in the drug-count response relationship in the two databases. In the FAERS, the maximum 
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myopathy risk goes to almost 1.0 as the dimension of drug combinations increases. Thus, a patient 
would be expected to experience a myopathy event if he/she takes a large number of drugs. On the 
other hand, the maximum myopathy risk in the INPC-CDM data is 0.72. However, because it was 
estimated from a case-control study, this number cannot be simply interpreted as a population 
maximum myopathy risk. Our 1:10 case control design has a higher myopathy case frequency (0.09) 
than the INPC-CDM population myopathy risk (0.067) reported previously (16). Hence, we anticipate 
that the population maximum HDDI myopathy risk in the INPC-CDM data is less than 0.72. While we 
observe that the maximum myopathy risk is higher in the FAERS database than in the INPC-CDM 
database, it is extremely striking that the frequency in FAERS approaches one. Although the maximum 
myopathy risk in the INPC-CDM data is lower than that of FAERS, it is still an extremely common ADE.  
 
Among the statistically significant three-way drug interactions identified from MDCM and validated by 
two databases, more stringent sequential comparisons are further conducted between 1-drug vs 2-drug 
and 2-drug vs 3-drugs. We further demonstrated that omeprazole, clonidine, and fluconazole, exhibited 
statistically significantly increased myopathy risk from single drug to three-drug combination in both 
databases.  
 
In parallel to our MDCM model, we evaluated the potential CYP PK interactions among the 30 drugs. In 
the IVIVE high dimensional drug interaction prediction, one drug acts as the substrate and the other 
drugs are assumed to be reversible inhibitors of CYP enzymes. Substrate AUCR changes were predicted 
based the curated in vitro PK data. The maximum predicted AUCR was reached with three-drug 
combinations. In contrast, the maximum HDDI myopathy risk observed in the two medical record 
databases did not occur until five drugs were co-administered. This suggests that additional mechanisms 
are responsible for the increased risk of myopathy observed with HDDIs. For instance, we have 
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previously shown that the increased risk myopathy with co-administration of loratadine and simvatstain 
is due to a pharmacodynamic mechanism in the muscle cell (17). We have also shown that the increased 
risk of myopathy observed when chloroquine is co-administered with simvastatin is the result of 
increased lysosomal OATP1B1 protein degradation (34). 
 
As the risk of myopathy consistently increased among 2-way and 3-way combinations of omeprazole, 
clonidine, and fluconazole, we closely examined the predicted AUCR using IVIVE for these combinations. 
Compared to the 1.5-5 fold increase in AUCR of R- and S-omeprazole when inhibited by only one drug, 
either clonidine or fluconazole, the co-administration of both drugs with omeprazole led to an AUCR of 
8.5-9.4. As fm is a critical component of predicting the extent of interaction, we evaluated the interaction 
using both in vitro data and data from clinical pharmacogenetic study of CYP2C19 to determine 
omeprazole’s fm. We estimated fmCYP2C19 (0.68) from in vitro data mining (35); Roman et al. estimated 
omeprazole clearance is decreased by 50% in CYP2C19 heterozygous patients (fmCYP2C19 = 0.5) (36); 
Venkatakrishnan et al. estimated fmCYP2C19 (0.87) from AUCR of CYP2C19 PMs (32, 33). The different 
fmCYP2C19 estimation results AUCR of omeprazole inhibit by clonidine and fluconazole range from 7.55-
11.74. Although the mechanism of omeprazole induced myopathy has not yet been understood, various 
hypotheses have been proposed such as the induction of auto-immune antibodies (37, 38), and the 
irreversible inhibition of potassium-hydrogen ATPase in the skeletal muscles (39).  
 
Recently, Sansone et al. surveyed the Italian National Network of Pharmacovigilance Database and 
found that omeprazole was more frequently involved in reports of myopathy than any other non-statin 
drug (40). From these evidences, omeprazole is the primary candidate that induced myopathy. In 
additional, there were sixteen case reports in the literature (41, 42)) and summarized in a case series 
that associate the use of omeprazole with myopathy (38). Among these sixteen cases, two were 
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identified as Asians, but the race were not reported among the other cases. Similarly, in our database, 
the race data were incomplete and sometimes inaccurate. Hence, the race effect of omeprazole induces 
myopathy remains unknown. 
One limitation of the MDCM model is its large computational expense. Because of this, only a limited 
number of drugs (i.e. 30) could be screened for high-dimensional drug interactions. Thus, screening 
steps are required to reduce the number of drugs. More research is needed to increase the 
computational efficiency of MDCM. Future research will also apply the MDCM model to evaluate the 
drug-count response patterns for other ADEs. 
Although the mechanistic static model is a well-accepted screening tool for pharmacokinetic drug 
interactions, it may over- or under-estimate the extent of interaction. Of note, our model only included 
reversible inhibition and did not consider gut wall metabolism effects of inhibitors. Thus, we may have 
under-estimated the AUCR for orally administered drugs. While mechanistic static models have been 
established to predict the effect of mechanism based inhibitors and CYP inducers (43, 44), these models 
have not been validated with respect to high-dimensional interactions among drugs that inhibit the 
same enzyme. Additionally, interactions in other pathways, such as drug transporters, could be included 
using more mechanistic and time-dependent modeling techniques. In addition, we utilized Cmax data 
from the literature without respect to the doses of drugs observed in the clinical records. 
This study demonstrates the power to elucidate clinically significant high-dimensional drug interactions 
from clinical records. Using two unique data sets, ADE case reports from the FAERS and structured 
electronic medical record data from the INPC-CDM, we observed increasing trends in myopathy risk with 
higher medication burden. As a large number of DDIs are the result of PK interactions at the level of CYP 
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enzymes, we also estimated the increased exposure of 9 substrate drugs in the presence of 2, 3, or more 
inhibitors. Although we demonstrated that decreased clearance of drugs due to CYP inhibition is one 
source of the increased myopathy risk among polypharmacy patients, this mechanism is unable to fully 
explain the increased risk of myopathy observed in subjects taking 4 or more medications. As our 
computational efficiency expands to allow for the evaluation of greater number of drugs using our 
MDCM model, additional pharmacokinetic and pharmacodynamic mechanisms of interaction will need 
to be considered to further account for the increased risk of ADEs observed in polypharmacy patients. 
Materials and Methods 
Indiana Network of Patient Care (INPC) Electronic Medical Record 
INPC-CDM data was derived from INPC patients between 2004 and 2015, following CDM Version 5.0 
guideline (http://omop.org/CDM). The INPC-CDM consists of structured data detailing medical 
conditions, medications, and lab tests of patients. Using this data set, we have identified myopathy 
patients, as defined in our previous paper (Duke et al., Table S6 (16)). The myopathy case definition 
contains both severe symptoms, such as rhabdomyolysis, and mild symptoms, such as muscle weakness. 
The myopathy cases include the first myopathy event recorded for a patient and cases in which no other 
myopathy event occurred within the past 6 months. For each case, ten controls were selected from 
records within the same time-frame (anchor time-matched) and matching demographic criteria. These 
controls did not have any myopathy events recorded in the INPC-CDM data set. Under each anchor time 
in both cases and matched controls, a one-month drug exposure window was generated. Drugs were 
coded as present if their prescription time periods overlapped with the drug exposure window. Drug 
names were normalized to their DrugBank IDs. The INPC-CDM data set has 450,673 cases and 4,506,730 
controls. This case/control design for the myopathy using the INPC-CDM database was similar to that 
used in our previous publications (17, 26, 44). 
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FDA Adverse Event Reporting System (FAERS) 
Unlike INPC-CDM, FAERS is a case reporting system, not a longitudinal database. In FAERS, myopathy 
cases were similarly identified using the same terms we used in the INPC-CDM (Table S1). There were 
136,791 myopathy cases, and 3,969,842 controls identified in the FAERS. The drug names were mapped 
to their DrugBank IDs. 
Drug Selection Criteria and Data Curation 
- Only FDA-approved drugs included 
- Selected by frequency >0.5% in both INPC and FAERS databases 
- Myopathy risk identified in SIDER 
- Limited to 30 drugs due to computational expense of MDCM 
Pharmacokinetic parameters required for in vitro in vivo extrapolation of AUCR (Cmax, fu, fm, Km, Vmax, Ki) 
were curated from Goodman and Gilman (45) or published literature identified in PubMed. Cmax 
obtained from literature review (45) was used as the inhibitor concentration [𝐼]. This conservative 
approach to estimate maximal inhibition has been used by others (46). If a pharmacokinetics parameter 
was reported in multiple sources, the sample mean was used. 
The fm data was curated from several different types of published studies. Most of the fm data were 
estimated from substrate depletion studies in human liver microsomes, in which the substrate is 
incubated with or without CYP-selective inhibitors (47). The percentage inhibition caused by the CYP-
selective inhibitor reflects the fm of drug for this CYP. The fm can also be estimated through in vivo 
pharmacokinetic studies comparing the AUC or clearance of a substrate in the presence and absence of 
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a CYP-selective inhibitor (48) or in a pharmacogenetic PK study where it can be calculated from the fold-
change in exposure of a victim drug in extensive metabolizers compared to poor metabolizers (26, 27). 
 
A Mixture Drug-Count-Response Model for the High-Dimensional Drug Effect on Myopathy 
In 2015, our group developed a mixture drug-count-response model (MDCM) for identifying high-
dimensional drug interaction-induced ADEs (26). In the MDCM, i is denoted as the number of drugs for i-
way drug combinations; j is the jth i-way drug combinations; 𝑛𝑖𝑗  is the total number of patients taking 
jth i-way drug combination; and 𝑦𝑖𝑗  is the number of cases among those 𝑛𝑖𝑗  patients. The parameter 𝜋 
represents the proportion of drug combinations that follow the drug-count-response model. The 
probability distribution of 𝑦𝑖𝑗  is defined as the following mixture model  
𝑃(𝑦𝑖𝑗) = (1 − 𝜋 )𝐵𝑖𝑛(𝑛𝑖𝑗 , 𝑦𝑖𝑗 , 𝑃𝑐𝑜𝑛𝑠𝑡) + 𝜋 𝐵𝑖𝑛(𝑛𝑖𝑗 , 𝑦𝑖𝑗 , 𝑃𝑐𝑜𝑢𝑛𝑡)            (Eq. 1) 
where 𝑃𝑐𝑜𝑛𝑠𝑡 and 𝑃𝑐𝑜𝑢𝑛𝑡  represent a constant ADE risk probability and a drug-count-response ADE risk 
probability respectively: 
𝑃𝑐𝑜𝑛𝑠𝑡 =
c×exp (𝛽0)
1+exp (𝛽0)
, 𝑃𝑐𝑜𝑛𝑠𝑡  =
c×exp (𝛽0+𝛽1(𝑖−1))
1+exp (𝛽0+𝛽1(𝑖−1))
.  
After applying MDCM to both FAERS and INPC-CDM data, a local false discovery rate (LFDR) is calculated 
for each drug combination. A LFDR demonstrates the significance of a drug combination that follows the 
drug-count-response model. Then, all the drug combinations are ranked based on the LFDR accordingly. 
𝐿𝐹𝐷𝑅 =
(1−𝜋)𝐵𝑖𝑛(𝑛𝑖𝑗,𝑦𝑖𝑗,𝑃𝑐𝑜𝑛𝑠𝑡)
(1−𝜋)𝐵𝑖𝑛(𝑛𝑖𝑗,𝑦𝑖𝑗,𝑃𝑐𝑜𝑛𝑠𝑡)+𝜋𝐵𝑖𝑛(𝑛𝑖𝑗,𝑦𝑖𝑗,𝑃𝑐𝑜𝑛𝑠𝑡)
                                (Eq. 2) 
This MDCM allows different drug combinations to share the same risk probabilities, either a constant 
risk or a drug-count-response risk. This strategy overcomes the small sample size in each high 
dimensional drug combination. In this paper, we evaluate the dimension of the drugs taken from single 
drug to 5 co-administered drugs.  
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Sensitivity Data Analysis 
Overlapping and mutually validated significant (LFDR < 0.05) high dimensional drug combinations 
between FAERS and INPC-CDM data were further evaluated. In the follow-up sensitivity analyses, a 
sequential logistic regression was conducted to compare myopathy risk between any two adjacent 
dimensions of drug combinations, for example 1-way vs 2-way, 2-way vs 3-way, etc. The logistic 
regression model included the demographic, and the number of other co-medications as covariates to 
adjust for the confounding effects. 
High Dimensional Drug Interaction in Vitro to in Vivo Extrapolation (IVIVE) 
A substrate’s clearance (CLtotal) is composed of hepatic clearance (CLH) and renal clearance (CLR), 
𝐶𝑙𝑡𝑜𝑡𝑎𝑙 = 𝐶𝑙𝐻 + 𝐶𝑙𝑅 . The ratio of area of under the concentration-time curve in the presence and 
absence of inhibitor (AUCR) is defined in (Eq 3), where C𝑙𝐻
′is the hepatic clearance of the substrate drug
after inhibition (49). 
AUCR =
𝐴𝑈𝐶′
𝐴𝑈𝐶
=
C𝑙𝑡𝑜𝑡𝑎𝑙
C𝑙𝑡𝑜𝑡𝑎𝑙
′ =
C𝑙𝐻+C𝑙𝑅
C𝑙𝐻
′+C𝑙𝑅
    (Eq. 3)     
Let the fraction of the renal clearance (𝑓𝑒) =
C𝑙𝑅
C𝑙𝐻+C𝑙𝑅
 , and C𝑙𝑅 = C𝑙𝐻 (
𝑓𝑒
1 − 𝑓𝑒
⁄ ), and the AUCR can be 
further defined as 
AUCR =
1
(1−𝑓𝑒)
C𝑙𝐻
′
C𝑙𝐻
+𝑓𝑒
For high clearance drugs in which CLint approaches hepatic blood flow, C𝑙𝐻 is limited by hepatic blood 
flow rate, and significant hepatic inhibition is unlikely. For the low clearance drugs, 
𝐶𝑙𝐻
′
𝐶𝑙𝐻
=
𝑓𝑢𝐶𝑙𝑖𝑛𝑡
′
𝑓𝑢𝐶𝑙𝑖𝑛𝑡
=
𝐶𝑙𝑖𝑛𝑡
′
𝐶𝑙𝑖𝑛𝑡
= ∑ 𝑓𝑚𝑖
𝐶𝑙𝑖𝑛𝑡,𝑖
′
𝐶𝑙𝑖𝑛𝑡,𝑖
, where 𝑓𝑚𝑖 is the fraction of metabolism by CYP enzyme (i) , and ∑ 𝑓𝑚𝑖
𝑛
𝑖=1 = 1 
where n is the number of metabolism routes. 
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When there is only one inhibitor and one metabolizing enzyme, Ito et al. (27, 49) showed that 
the change in clearance in the presence of a DDI can be predicted as 
𝐶𝑙𝑖𝑛𝑡,𝑖
′
𝐶𝑙𝑖𝑛𝑡,𝑖
=
1
1+
[𝐼]
𝑘𝑖
, where[𝐼] is fraction 
unbound concentration of the inhibitor and Ki is the competitive inhibition constant. If there are 
inhibitors on the same enzyme, the inhibitors’ effects are assumed to fit an additive model (50). The 
AUCR for inhibition of a single enzyme then becomes 
𝐴𝑈𝐶𝑅 =  
𝐶𝑙𝑖𝑛𝑡,𝑖
′
𝐶𝑙𝑖𝑛𝑡,𝑖
=
1
1+(∑
[𝐼𝑗]
𝑘𝑖𝑗
𝐽
𝑗=1 )
When considering multiple inhibitors and multiple enzyme pathways, the AUCR is predicted by equation 
4 (46): 
𝐴𝑈𝐶𝑅 =
1
(1−𝑓𝑒) ∑ 𝑓𝑚𝑖×
1
1+(∑
[𝐼𝑗]
𝑘𝑖𝑗
𝐽
𝑗=1
)
𝑛
𝑖=1  + 𝑓𝑒
  (Eq. 4) 
We used this method to predict the AUCR for each substrate drug in the presence of 1- to 4- inhibitors.. 
Study Highlights 
What is the current knowledge on the topic? 
High dimensional drug interactions are occasionally investigated in vitro, but rarely done in pharmaco-
epidemiology studies. 
What question did this study address? 
For the first time, this paper discovers and validates high dimensional drug interaction induced 
myopathy using two independent health record databases. This paper further investigates their 
pharmacokinetics mechanisms through the in vitro in vivo extrapolation. 
What does this study add to our knowledge? 
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Using the mixture drug-count-response model (MDCM), for the first time, this paper estimates the 
maximum high dimensional drug interaction induced myopathy risks. In particular, the maximum 
myopathy risk reaches 1.0 in the FAERS. 
How might this change clinical pharmacology or translational science? 
Using both IVIVE high dimensional drug interaction AUCR prediction and MDCM based data mining from 
two databases, we demonstrate the significantly increased myopathy risk among (omeprazole, clonidine, 
fluconazole), and via inhibition of CYP3A and CYP2C19 enzymes. 
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Figure Legends 
Figure 1: Drugs selection flow chart 
Figure 2: Mixture dose-count model curve for both INPC and FAERS data. Red dash line is the constant 
risk estimated; Blue dash line is maximum risk estimated; Green dash line is drug count response risk 
estimated. 
Figure 3: Overlapped drug combination between INPC and FAERS dataset with LFDR < 0.05 
Figure4: Simulated AUCR of 2-way to 5-way drugs combination. Only AUCR>=1.25 are reported here. 
Figure 5: Group-wise odds ratio analysis; OMZ is omeprazole or esomeprazole; CLN is clonidine; FLU is 
fluconazole 
Figure 6: Hepatic metabolism and drug interactions between omeprazole, clonidine, and fluconazole. 
Tables 
Table 1: Top 28 3-way drugs interaction combination. G12 and G23 means the p-value of odds ratio 
compared taken 1 of 3 drugs vs 2 of 3 drugs, and taken 2 of 3 drugs and 3 of 3 drugs. a. Combine analysis: 
treated omeprazole and esomeprazole as same drug. 
Supplemental Material 
Table S1: Phenotype definition 
Table S2: fm and fe 
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Table 1: Top 28 3-way drugs interaction combination. G12 and G23 means the p-value of odds ratio compared taken 1 of 3 drugs vs 2 of 3 drugs, and taken 2 of 3 drugs and 3 of 3 
drugs. a. Combine analysis: treated omeprazole and esomeprazole as same drug. 
Drugs LFDR AUCR INPC-CDM FAERS 
Substrate Inhibitor 1 Inhibitor 2 INPC FAERS AUCR AUCR1 AUCR2 OR Total Case G12 G23 OR Total Case G12 G23 
omeprazole fluconazole clonidine 5.67E-03 2.68E-03 9.35 5.06 1.45 18.46 37 24 2.64E-12 4.18E-01 6.41 105 19 1.38E-01 2.00E-01 
esomeprazole fluconazole clonidine 1.40E-04 7.14E-12 8.51 5.17 1.35 36.67 28 22 1.34E-04 4.35E-02 13.04 100 31 1.09E-01 7.64E-06 
a- omeprazole/ 
esomeprazole clonidine fluconazole 24.21 7.77E-13 6.88E-02 8.73 1.15E-02 1.22E-05 
esomeprazole fluconazole acetaminophen 4.22E-14 5.38E-04 5.20 5.17 1.01 18.77 279 182 5.13E-05 5.06E-02 5.20 922 140 3.75E-07 9.67E-02 
esomeprazole fluconazole trazodone 6.57E-04 2.78E-06 5.19 5.17 1.01 17.31 71 45 3.83E-24 8.04E-01 10.45 68 18 1.22E-01 1.04E-01 
esomeprazole fluconazole fentanyl 7.06E-08 2.28E-15 5.18 5.17 1.01 39.09 54 43 2.88E-24 4.96E-01 8.09 303 66 6.21E-18 2.30E-01 
esomeprazole fluconazole metoclopramide 3.40E-06 1.29E-09 5.17 5.17 1.00 36.67 42 33 1.20E-09 9.91E-02 6.46 368 67 1.66E-01 9.00E-01 
esomeprazole fluconazole tramadol 1.76E-02 3.69E-10 5.17 5.17 1.00 15.88 44 27 4.70E-03 4.40E-01 8.69 165 38 1.42E-01 2.76E-02 
esomeprazole fluconazole levofloxacin 9.02E-03 1.41E-23 5.17 5.17 1.00 16.88 43 27 1.29E-16 6.44E-01 9.15 363 87 7.19E-01 8.97E-01 
esomeprazole fluconazole ciprofloxacin 1.06E-03 4.06E-14 5.17 5.17 1.00 18.42 54 35 1.68E-05 1.00E-01 7.02 411 80 4.42E-04 2.95E-01 
omeprazole fluconazole acetaminophen 1.25E-21 4.09E-13 5.10 5.06 1.02 18.67 450 293 3.78E-48 4.57E-02 5.67 1109 181 1.28E-01 4.15E-01 
omeprazole fluconazole trazodone 4.12E-04 6.72E-16 5.08 5.06 1.01 18.26 65 42 4.48E-52 7.03E-01 12.74 141 43 4.50E-01 6.23E-04 
omeprazole fluconazole fentanyl 1.07E-05 3.97E-16 5.08 5.06 1.01 27.69 49 36 4.33E-49 5.47E-01 7.85 343 73 1.21E-03 7.31E-01 
omeprazole fluconazole paroxetine 1.69E-02 1.88E-06 5.06 5.06 1.00 18.00 28 18 1.00E-04 1.70E-01 7.38 148 30 1.94E-03 9.55E-01 
omeprazole fluconazole diclofenac 2.42E-02 2.04E-03 5.06 5.06 1.00 17.78 25 16 8.62E-08 2.30E-01 6.61 97 18 3.57E-01 7.10E-03 
omeprazole fluconazole levofloxacin 2.09E-03 1.93E-37 5.06 5.06 1.00 17.50 55 35 6.35E-25 4.23E-01 9.94 502 128 6.16E-02 5.28E-07 
loratadine fluconazole tramadol 2.11E-03 1.37E-03 3.13 2.65 1.06 22.00 32 22 4.50E-09 6.91E-01 7.52 68 14 8.59E-01 5.49E-01 
loratadine clonidine metoclopramide 2.70E-02 2.40E-02 2.86 2.84 1.00 26.67 11 8 1.74E-05 6.80E-01 7.81 33 7 3.91E-04 8.40E-01 
loratadine clonidine levofloxacin 1.27E-03 4.50E-03 2.84 2.84 1.00 N/A 10 10 7.61E-05 6.96E-01 8.06 46 10 4.58E-01 7.91E-01 
loratadine fluconazole fentanyl 2.32E-02 2.64E-04 2.68 2.65 1.02 35.00 9 7 3.63E-16 6.77E-01 7.46 88 18 1.61E-05 6.22E-01 
loratadine fluconazole acetaminophen 2.57E-19 1.31E-04 2.67 2.65 1.04 39.34 148 118 3.97E-86 3.21E-03 5.86 262 44 1.19E-03 3.68E-01 
loratadine fluconazole metoclopramide 2.50E-03 1.17E-04 2.67 2.65 1.00 100.00 11 10 1.49E-07 2.06E-01 8.88 64 15 1.28E-01 4.15E-01 
loratadine fluconazole levofloxacin 2.14E-04 1.02E-09 2.65 2.65 1.00 80.00 18 16 9.40E-07 6.35E-02 10.24 115 30 4.97E-02 1.16E-01 
venlafaxine tramadol clonidine 5.74E-03 2.47E-07 2.30 2.03 1.06 36.67 14 11 5.97E-08 1.18E-01 11.38 71 20 6.26E-03 5.49E-03 
venlafaxine tramadol fentanyl 1.83E-05 2.69E-29 2.06 2.03 1.03 73.34 25 22 1.30E-22 4.55E-02 15.96 203 72 9.58E-21 1.33E-09 
venlafaxine tramadol trazodone 6.48E-06 7.86E-13 2.06 2.03 1.03 18.00 112 72 2.39E-25 2.05E-01 7.72 281 59 1.64E-05 1.97E-03 
venlafaxine tramadol metoclopramide 7.86E-04 8.81E-16 2.05 2.03 1.02 28.57 27 20 3.39E-16 3.34E-01 12.16 149 44 1.56E-09 4.52E-05 
venlafaxine tramadol ciprofloxacin 1.60E-02 3.45E-12 2.05 2.03 1.00 16.92 35 22 1.30E-20 5.76E-01 14.51 90 30 8.54E-05 5.01E-02 
venlafaxine tramadol acetaminophen 7.15E-17 1.05E-14 2.05 2.03 1.00 17.87 390 250 1.52E-59 1.07E-01 6.10 766 133 2.09E-16 1.04E-04 
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